Royalty Pharma agreed to pay Neurimmune $125 million upfront for a royalty interest in cliramitug, a TTR-fibril-depleting antibody designed to clear amyloid deposits in transthyretin amyloidosis with cardiomyopathy. The transaction also includes an additional $125 million due in the first quarter of 2027 and $175 million in contingent milestone payments tied to clinical and regulatory outcomes. Cliramitug is being evaluated in the Phase III DepleTTR-CM trial, with results expected in 2028. Neurimmune said the deal funds internal R&D while retaining most royalty and milestone interests, and AstraZeneca has previously projected peak sales in the $3 billion to $5 billion range for the asset.